Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer’s Disease and Other Tauopathies

Journal of Neuroimmune Pharmacology

Volumn 11, Issue 1, 2016, Pages 9-25

  Schroeder, Sulana K ^a   Joly Amado, Aurelie ^a   Gordon, Marcia N ^a   Morgan, Dave ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Active immunization; Dementia; Gallyas; Passive immunization; rTg4510; Tau; Transgenic mice; Vaccination

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CD11B ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; INTERLEUKIN 1BETA; INTERLEUKIN 6; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; PYRIDOXAL 5 PHOSPHATE; TAU PROTEIN; IMMUNOLOGICAL ADJUVANT;

ACTIVE IMMUNIZATION; ALLERGIC ENCEPHALITIS; ALZHEIMER DISEASE; BRAIN NERVE CELL; CLINICAL TRIAL (TOPIC); ENCEPHALOMYELITIS; HIPPOCAMPUS; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAZE TEST; MICROGLIA; MOTOR PERFORMANCE; NONHUMAN; OSMOTIC PUMP; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; IMMUNOLOGY; PROCEDURES; TAUOPATHIES; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE, TRANSGENIC; TAU PROTEINS; TAUOPATHIES;

EID: 84957439174     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-015-9637-6     Document Type: Review

References (70)

1. Agadjanyan MG, Petrovsky N, Ghochikyan A (2015) A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer’s disease. Alzheimer’s Dementia: J Alzheimer’s Assoc. doi: 10.1016/j.jalz.2015.06.1884
2. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115–9129
3. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64:94–101
4. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6, e26860
5. Billiau A, Matthys P (2001) Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 70:849–860
6. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224:472–485
7. Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30:16559–16566
8. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118:658–667
9. Braak H, Braak E, Bohl J (1993) Staging of Alzheimer-related cortical destruction. Eur Neurol 33:403–408
10. Brownlow ML, Joly-Amado A, Azam S, Elza M, Selenica ML, Pappas C, Small B, Engelman R, Gordon MN, Morgan D (2014) Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. Behav Brain Res 271:79–88
11. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Trojanowski JQ (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 30:13861–13866
12. Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE, Gordon MN, Morgan D, Nash K (2010) Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods 194:144–153
13. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Kayed R (2014a) Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis 40(Suppl 1):S97–S111
14. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R (2014b) Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34:4260–4272
15. Castrillo JI, Oliver SG (2016) Alzheimer’s as a systems-level disease involving the interplay of multiple cellular networks. Methods Mol Biol (Clifton, NJ) 1303:3–48
16. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286:34457–34467
17. Citron M (2010) Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 9:387–398
18. ClinicalTrials.gov identifier: NCT01850238, Axon Neuroscience SE (2013)
19. Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F (2014) Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain: J Neurol 137:2834–2846
20. d'Abramo C, Acker C, Jimenez H, Davies P (2013) Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE 8:10
21. Denk F, Wade-Martins R (2009) Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging 30:1–13
22. Ding WX, Yin XM (2008) Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 4:141–150
23. Espinoza M, de Silva R, Dickson DW, Davies P (2008) Differential incorporation of tau isoforms in Alzheimer’s disease. J Alzheimers Dis 14:1–16
24. Fontaine SN, Rauch JN, Nordhues BA, Assimon VA, Stothert AR, Jinwal UK, Sabbagh JJ, Chang L, Stevens SM Jr, Zuiderweg ER, Gestwicki JE, Dickey CA (2015) Isoform-selective genetic inhibition of constitutive cytosolic Hsp70 activity promotes client Tau degradation using an altered co-chaperone complement. J Biol Chem 290:13115–13127
25. Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, Agadjanyan MG (2006) Prototype Alzheimer’s disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 24:2275–2282
26. Gotz J, Ittner A, Ittner LM (2012) Tau-targeted treatment strategies in Alzheimer’s disease. Br J Pharmacol 165:1246–1259
27. Guerrero-Munoz MJ, Castillo-Carranza DL, Kayed R (2014) Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem Pharmacol 88:468–478
28. Halle M, Tribout-Jover P, Lanteigne AM, Boulais J, St-Jean JR, Jodoin R, Girouard MP, Constantin F, Migneault A, Renaud F, Didierlaurent AM, Mallett CP, Burkhart D, Pilorget A, Palmantier R, Larocque D (2015) Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. J Immunol Methods 424:64–79
29. Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI (2012) Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther 136:8–22
30. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68:1067–1081
31. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287:19440–19451
32. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R (2011a) Tau oligomers as potential target for immunotherapy for Alzheimer disease and tauopathies. Curr Alzheimer Res 8:659–665
33. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R (2011b) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6:39
34. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R (2012a) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Scientific Reports 2:700
35. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R (2012b) Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J: Off Publ Federation Am Soc Exp Biol 26:1946–1959
36. Lashley T, Rohrer JD, Mead S, Revesz T (2015) Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol. doi: 10.1111/nan.12250
37. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121–1159
38. Lemere CA (2013) Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener 8:36
39. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul MM, M. Baker, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P and Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402–405
40. Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harbor Perspectives Med 2:a006247
41. Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, Trinczek B, Mandelkow E (1996) Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y Acad Sci 777:96–106
42. Medeiros R, Baglietto-Vargas D, LaFerla FM (2011) The role of tau in Alzheimer’s disease and related disorders. CNS Neurosci Ther 17:514–524
43. Morgan D (2011) Immunotherapy for Alzheimer’s disease. J Intern Med 269:54–63
44. Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70:410–426
45. Oddo S, Caccamo A, Cheng D, LaFerla FM (2009) Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol 19:421–430
46. O'Leary JC 3rd, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, Jinwal UK, Koren J 3rd, Jones JR, Kraft C, Peters M, Abisambra JF, Duff KE, Weeber EJ, Gestwicki JE, Dickey CA (2010) Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 5:45
47. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46–54
48. Ragupathi G, Damani P, Deng K, Adams MM, Hang J, George C, Livingston PO, Gin DY (2010) Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins. Vaccine 28:4260–4267
49. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal Tau protein. Arch Neurol 63:1459–1467
50. Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, Karussis D, Rosenmann H (2013) Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 248:451–456
51. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476–481
52. Selenica ML, Brownlow M, Jimenez JP, Lee DC, Pena G, Dickey CA, Gordon MN, Morgan D (2013) Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neuro-Degenerative Dis 11:165–181
53. Selenica ML, Davtyan H, Housley SB, Blair LJ, Gillies A, Nordhues BA, Zhang B, Liu J, Gestwicki JE, Lee DC, Gordon MN, Morgan D, Dickey CA (2014) Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation 11:152
54. Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J Alzheimers Dis 15:157–168
55. Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer’s disease and related tauopathies. Curr Alzheimer Res 6:446–450
56. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M (2012) Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11:241–249
57. Sui D, Liu M, Kuo MH (2015) In vitro aggregation assays using hyperphosphorylated tau protein. J Vis Exp 2(95):e51537
58. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9:397–405
59. Utton MA, Noble WJ, Hill JE, Anderton BH, Hanger DP (2005) Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J Cell Sci 118:4645–4654
60. Walls KC, Ager RR, Vasilevko V, Cheng D, Medeiros R, LaFerla FM (2014) p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett 575:96–100
61. Wang Y, Mandelkow E (2012) Degradation of tau protein by autophagy and proteasomal pathways. Biochem Soc Trans 40:644–652
62. Wang JZ, Gao X, Wang ZH (2014) The physiology and pathology of microtubule-associated protein tau. Essays Biochem 56:111–123
63. Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15:555–569
64. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24:6144–6151
65. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN (2007) Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144:950–960
66. Wisniewski T, Boutajangout A (2010) Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models. Brain Struct Funct 214:201–218
67. Wolfe MS (2012) The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica 2012:796024
68. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM (2011) In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31:13110–13117
69. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80:402–414
70. Yu X, Luo Y, Dinkel P, Zheng J, Wei G, Margittai M, Nussinov R, Ma B (2012) Cross-seeding and conformational selection between three- and four-repeat human Tau proteins. J Biol Chem 287:14950–14959